Cabaletta Bio, Inc.
CABACabaletta Bio, Inc. in brief
Cabaletta Bio, Inc. is a listed company in the Biotechnology industry, based in Philadelphia, Pennsylvania, USA. Its market value was $343 M on 30 October 2026, which makes it the 14,222nd largest listed company in the world and the 2,783rd largest in the USA on this site. It employs about 156 people and Steven Nichtberger is its chief executive. Its shares trade under the symbol CABA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Cabaletta Bio, Inc.
We are a late clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Our proprietary CABA®, or Cabaletta Approach to B cell Ablation platform, focuses on the CARTA approach. CARTA refers to Chimeric Antigen Receptor T cells for Autoimmunity and is designed to potentially reset the immune system. Based on clinical data reported to date, we believe our CABA® platform has the potential to safely enable complete and durable responses for a broad range of autoimmune diseases and that it has potential applicability across dozens of autoimmune diseases that we have identified, evaluated and prioritized.
From the company's annual report filed with the US SEC: read the report
Cabaletta Bio, Inc. timeline
- 2018
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2019
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 25 October 2019; shares registered for exchange trading on 23 October 2019.
Events of Cabaletta Bio, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,864 (Jan 2020) · #2,954 (Jan 2021) · #4,423 (Jan 2022) · #3,461 (Dec 2022) · #2,686 (Jul 2023) · #2,079 (Jan 2024) · #1,521 (Mar 2026) · #2,600 (Aug 2026) · #2,626 (Oct 2026) · #2,787 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 3.1×
- Free cash flow yield
- -38.6%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -149.8%
- Liabilities / assets
- 32.1%
- Profit per employee
- $-1.1 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-172M | $-168M | — |
| Dec 2024 | — | — | $-125M | $-116M | — |
| Dec 2023 | — | — | $-75M | $-68M | — |
| Dec 2022 | — | — | $-54M | $-53M | — |
| Dec 2021 | — | — | $-46M | $-46M | — |
| Dec 2020 | — | — | $-34M | $-33M | — |
| Dec 2019 | — | — | $-19M | $-17M | — |
| Dec 2018 | — | — | $-6M | $-12M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-131M | $1M | $-132M | $-2.10 | — |
| Dec 2024 | $-88M | $2M | $-90M | $-2.34 | — |
| Dec 2023 | $-54M | $1M | $-54M | $-1.65 | — |
| Dec 2022 | $-46M | $2M | $-49M | $-1.81 | — |
| Dec 2021 | $-34M | $1M | $-35M | $-1.80 | — |
| Dec 2020 | $-27M | $1M | $-27M | $-1.44 | — |
| Dec 2019 | $-16M | $1M | $-17M | $-4.07 | $0.00 |
| Dec 2018 | $-5M | — | — | $-6.87 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-53M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 20268-KCurrent reportRegulation FD disclosure · Other events
- Nov 5, 202610-QQuarterly report · period to Sep 2026
- Nov 5, 20268-KCurrent reportResults of operations
- Sep 14, 20268-KCurrent reportOther events
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Jun 11, 20268-KCurrent reportBylaws amended · Shareholder vote
- Jun 3, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 14, 202610-QQuarterly report · period to Mar 2026
- May 14, 20268-KCurrent reportResults of operations
- May 14, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 4, 20268-KCurrent reportMaterial agreement · Results of operations · Other events
Official filings of Cabaletta Bio, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-172 M
- Net income
- $-168 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $165 M
- Total liabilities
- $53 M
- Total equity
- $112 M
As of December-2025
Top 100 institutional investors in Cabaletta Bio, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Jennison Associates LLC | 25,145,918 | +5,112,188 (+25.52%) | 11.66% | $48 M | Nov 16, 2026 |
| 2 | Bain Capital Life Sciences Investors, LLC | 21,209,188 | +3,967,743 (+23.01%) | 9.83% | $41 M | Nov 16, 2026 |
| 3 | T. Rowe Price Investment Management, Inc. | 17,250,098 | -1,619,809 (-8.58%) | 8.00% | $33 M | Nov 16, 2026 |
| 4 | BlackRock, Inc. | 14,381,113 | +3,626,412 (+33.72%) | 6.67% | $28 M | Nov 13, 2026 |
| 5 | Adage Capital Partners GP, L.L.C. | 14,174,758 | +5,000,000 (+54.50%) | 6.57% | $27 M | Nov 16, 2026 |
| 6 | State Street Corp | 8,053,077 | +213,772 (+2.73%) | 3.73% | $15 M | Nov 12, 2026 |
| 7 | Vanguard Capital Management LLC | 7,144,758 | -82,260 (-1.14%) | 3.31% | $14 M | Nov 13, 2026 |
| 8 | Price T Rowe Associates Inc /MD/ | 6,235,788 | +1,817,114 (+41.12%) | 2.89% | $12 M | Nov 16, 2026 |
| 9 | Woodline Partners LP | 5,200,642 | +1,000,500 (+23.82%) | 2.41% | $10 M | Nov 16, 2026 |
| 10 | Alyeska Investment Group, L.P. | 4,500,000 | New | 2.09% | $9 M | Nov 16, 2026 |
| 11 | Cormorant Asset Management, LP | 4,500,000 | -500,000 (-10.00%) | 2.09% | $9 M | Nov 16, 2026 |
| 12 | Geode Capital Management, LLC | 4,276,647 | +817,183 (+23.62%) | 1.98% | $8 M | Nov 6, 2026 |
| 13 | Goldman Sachs Group Inc | 4,267,406 | +2,055,581 (+92.94%) | 1.98% | $8 M | Nov 16, 2026 |
| 14 | Citadel Advisors LLC | 2,710,391 | -811,721 (-23.05%) | 1.26% | $5 M | Nov 16, 2026 |
| 15 | Heights Capital Management, Inc | 2,500,000 | +1,744,374 (+230.85%) | 1.16% | $5 M | Nov 16, 2026 |
| 16 | Franklin Templeton Inc | 2,413,937 | 0 (0.00%) | 1.12% | $5 M | Nov 12, 2026 |
| 17 | Morgan Stanley | 2,351,096 | +1,005,570 (+74.73%) | 1.09% | $5 M | Nov 13, 2026 |
| 18 | Opaleye Management Inc. | 2,321,602 | -1,542,198 (-39.91%) | 1.08% | $4 M | Nov 16, 2026 |
| 19 | Vanguard Portfolio Management LLC | 2,279,377 | +861,269 (+60.73%) | 1.06% | $4 M | Nov 13, 2026 |
| 20 | Qube Research & Technologies Ltd | 2,106,718 | +679,878 (+47.65%) | 0.98% | $4 M | Nov 13, 2026 |
| 21 | Propel Bio Management, LLC | 2,049,471 | New | 0.95% | $4 M | Nov 13, 2026 |
| 22 | Diametric Capital, LP | 1,872,614 | +1,737,016 (+1281.00%) | 0.87% | $4 M | Nov 16, 2026 |
| 23 | UBS Group AG | 1,644,876 | +172,981 (+11.75%) | 0.76% | $3 M | Nov 10, 2026 |
| 24 | Marshall Wace, LLP | 1,543,867 | -22,072 (-1.41%) | 0.72% | $3 M | Nov 13, 2026 |
| 25 | FMR LLC | 1,498,801 | +1,482,873 (+9309.85%) | 0.69% | $3 M | Nov 10, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Northern Trust Corp | 1,298,836 | +291,734 (+28.97%) | 0.60% | $2 M | Nov 16, 2026 |
| 27 | Sphera Funds Management LTD. | 1,263,612 | -65,400 (-4.92%) | 0.59% | $2 M | Nov 16, 2026 |
| 28 | Cantor Fitzgerald, L. P. | 1,211,629 | -388,373 (-24.27%) | 0.56% | $2 M | Nov 16, 2026 |
| 29 | Occam Crest Management LP | 1,190,000 | New | 0.55% | $2 M | Nov 13, 2026 |
| 30 | Dimensional Fund Advisors LP | 1,189,152 | +221,957 (+22.95%) | 0.55% | $2 M | Nov 4, 2026 |
| 31 | Vanguard Fiduciary Trust Co | 1,095,231 | +6,636 (+0.61%) | 0.51% | $2 M | Nov 13, 2026 |
| 32 | Two Sigma Investments, LP | 1,036,927 | -374,004 (-26.51%) | 0.48% | $2 M | Nov 16, 2026 |
| 33 | Nuveen, LLC | 1,030,976 | +384,631 (+59.51%) | 0.48% | $2 M | Nov 10, 2026 |
| 34 | Schroder Investment Management Group | 870,268 | +13,631 (+1.59%) | 0.40% | $2 M | Nov 16, 2026 |
| 35 | Ameriprise Financial Inc | 828,238 | +93 (+0.01%) | 0.38% | $2 M | Nov 16, 2026 |
| 36 | Susquehanna Portfolio Strategies, LLC | 734,855 | +351,561 (+91.72%) | 0.34% | $1 M | Nov 16, 2026 |
| 37 | Ikarian Capital, LLC | 700,000 | 0 (0.00%) | 0.32% | $1 M | Nov 16, 2026 |
| 38 | Burkehill Global Management, LP | 700,000 | 0 (0.00%) | 0.32% | $1 M | Nov 16, 2026 |
| 39 | Squarepoint Ops LLC | 698,145 | New | 0.32% | $1 M | Nov 9, 2026 |
| 40 | TD Asset Management Inc | 651,472 | +260,000 (+66.42%) | 0.30% | $1 M | Nov 13, 2026 |
| 41 | Millennium Management LLC | 640,361 | -1,428,130 (-69.04%) | 0.30% | $1 M | Nov 16, 2026 |
| 42 | Simplify Asset Management Inc. | 556,235 | New | 0.26% | $1 M | Oct 27, 2026 |
| 43 | Stonepine Capital Management, LLC | 520,000 | -397,100 (-43.30%) | 0.24% | $1 M | Nov 13, 2026 |
| 44 | Superstring Capital Management LP | 517,412 | -761,240 (-59.53%) | 0.24% | $1 M | Nov 16, 2026 |
| 45 | Charles Schwab Investment Management Inc | 514,582 | +139,696 (+37.26%) | 0.24% | $1 M | Nov 16, 2026 |
| 46 | KVP Capital Advisors, LP | 505,431 | 0 (0.00%) | 0.23% | $1 M | Nov 16, 2026 |
| 47 | Gsa Capital Partners LLP | 475,720 | -192,843 (-28.84%) | 0.22% | $1 M | Nov 16, 2026 |
| 48 | XTX Topco Ltd | 466,072 | +420,370 (+919.81%) | 0.22% | $1 M | Nov 16, 2026 |
| 49 | Bank Of America Corp /de/ | 430,489 | -62,825 (-12.74%) | 0.20% | $1 M | Nov 16, 2026 |
| 50 | Mackenzie Financial Corp | 416,161 | New | 0.19% | $1 M | Nov 2, 2026 |
| 51 | Raiffeisen Bank International AG | 400,000 | -30,000 (-6.98%) | 0.19% | $1 M | Oct 28, 2026 |
| 52 | Wellington Management Group LLP | 389,099 | +102,887 (+35.95%) | 0.18% | $1 M | Nov 16, 2026 |
| 53 | Manufacturers Life Insurance Company, The | 385,775 | +203,720 (+111.90%) | 0.18% | $1 M | Nov 13, 2026 |
| 54 | Bank of New York Mellon Corp | 384,738 | +79,919 (+26.22%) | 0.18% | $1 M | Nov 5, 2026 |
| 55 | Barclays PLC | 334,450 | +289,749 (+648.19%) | 0.15% | $1 M | Nov 6, 2026 |
| 56 | US Bancorp \de\ | 273,107 | +256,614 (+1555.90%) | 0.13% | $1 M | Nov 5, 2026 |
| 57 | Renaissance Technologies LLC | 272,700 | -1,262,600 (-82.24%) | 0.13% | $1 M | Nov 12, 2026 |
| 58 | Invesco Ltd. | 249,498 | +7,933 (+3.28%) | 0.12% | $0 M | Nov 12, 2026 |
| 59 | Susquehanna International Group, LLP | 245,275 | +182,047 (+287.92%) | 0.11% | $0 M | Nov 16, 2026 |
| 60 | Rafferty Asset Management, LLC | 214,615 | +68,508 (+46.89%) | 0.10% | $0 M | Nov 13, 2026 |
| 61 | Los Angeles Capital Management LLC | 195,544 | +161,125 (+468.13%) | 0.09% | $0 M | Nov 12, 2026 |
| 62 | Boothbay Fund Management, LLC | 182,455 | 0 (0.00%) | 0.08% | $0 M | Nov 16, 2026 |
| 63 | Panagora Asset Management Inc | 157,953 | -3,963 (-2.45%) | 0.07% | $0 M | Nov 12, 2026 |
| 64 | Rhumbline Advisers | 156,850 | +25,210 (+19.15%) | 0.07% | $0 M | Nov 10, 2026 |
| 65 | BNP Paribas Financial Markets | 152,959 | +133,350 (+680.04%) | 0.07% | $0 M | Nov 12, 2026 |
| 66 | Deutsche Bank AG\ | 139,880 | +28,918 (+26.06%) | 0.06% | $0 M | Nov 6, 2026 |
| 67 | Prelude Capital Management, LLC | 132,617 | +122,528 (+1214.47%) | 0.06% | $0 M | Nov 16, 2026 |
| 68 | Alliancebernstein L.P. | 108,410 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 69 | Virtus Investment Advisers, LLC | 105,427 | -3,276 (-3.01%) | 0.05% | $0 M | Nov 12, 2026 |
| 70 | Almitas Capital LLC | 103,860 | -22,040 (-17.51%) | 0.05% | $0 M | Nov 17, 2026 |
| 71 | LPL Financial LLC | 102,953 | +23,878 (+30.20%) | 0.05% | $0 M | Nov 6, 2026 |
| 72 | EntryPoint Capital, LLC | 102,763 | +51,836 (+101.78%) | 0.05% | $0 M | Nov 13, 2026 |
| 73 | Bridgeway Capital Management, LLC | 98,875 | -168,497 (-63.02%) | 0.05% | $0 M | Nov 16, 2026 |
| 74 | Citigroup Inc | 98,076 | -86,156 (-46.76%) | 0.05% | $0 M | Nov 4, 2026 |
| 75 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 95,474 | +26,882 (+39.19%) | 0.04% | $0 M | Nov 16, 2026 |
| 76 | MetLife Investment Management, LLC | 94,772 | +28,023 (+41.98%) | 0.04% | $0 M | Nov 16, 2026 |
| 77 | Jpmorgan Chase & Co | 93,226 | +33,858 (+57.03%) | 0.04% | $0 M | Nov 12, 2026 |
| 78 | Letko, Brosseau & Associates Inc | 90,475 | 0 (0.00%) | 0.04% | $0 M | Nov 6, 2026 |
| 79 | Empowered Funds, LLC | 85,675 | New | 0.04% | $0 M | Nov 13, 2026 |
| 80 | AQR Capital Management LLC | 80,840 | New | 0.04% | $0 M | Nov 16, 2026 |
| 81 | Point72 Asset Management, L.P. | 78,671 | New | 0.04% | $0 M | Nov 16, 2026 |
| 82 | Profund Advisors LLC | 75,960 | +2,551 (+3.48%) | 0.04% | $0 M | Oct 29, 2026 |
| 83 | ExodusPoint Capital Management, LP | 74,961 | New | 0.03% | $0 M | Nov 16, 2026 |
| 84 | Graham Capital Management, L.P. | 74,755 | -6,524 (-8.03%) | 0.03% | $0 M | Nov 16, 2026 |
| 85 | Brevan Howard Capital Management LP | 74,106 | New | 0.03% | $0 M | Nov 16, 2026 |
| 86 | Creative Planning | 72,256 | New | 0.03% | $0 M | Nov 2, 2026 |
| 87 | Persistent Asset Partners Ltd | 60,466 | +55,823 (+1202.30%) | 0.03% | $0 M | Nov 13, 2026 |
| 88 | Grey Ledge Advisors, LLC | 60,000 | +30,000 (+100.00%) | 0.03% | $0 M | Nov 2, 2026 |
| 89 | Vanguard Global Advisers, LLC | 58,153 | +781 (+1.36%) | 0.03% | $0 M | Nov 13, 2026 |
| 90 | Matauro, LLC | 55,108 | 0 (0.00%) | 0.03% | $0 M | Nov 3, 2026 |
| 91 | Universal- Beteiligungs- und Servicegesellschaft mbH | 54,086 | 0 (0.00%) | 0.03% | $0 M | Nov 10, 2026 |
| 92 | Ieq Capital, LLC | 53,978 | New | 0.03% | $0 M | Nov 10, 2026 |
| 93 | Quadrature Capital Ltd | 50,137 | New | 0.02% | $0 M | Nov 13, 2026 |
| 94 | Police & Firemen's Retirement System of New Jersey | 47,368 | +14,165 (+42.66%) | 0.02% | $0 M | Nov 9, 2026 |
| 95 | Wells Fargo & Company/mn | 47,286 | -149,586 (-75.98%) | 0.02% | $0 M | Nov 16, 2026 |
| 96 | Virtu Financial LLC | 46,626 | -22,885 (-32.92%) | 0.02% | $0 M | Nov 17, 2026 |
| 97 | Engineers Gate Manager LP | 41,085 | New | 0.02% | $0 M | Nov 16, 2026 |
| 98 | ADAR1 Capital Management, LLC | 40,000 | -10,000 (-20.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 99 | Keybank National Association/oh | 39,005 | 0 (0.00%) | 0.02% | $0 M | Nov 4, 2026 |
| 100 | Simplex Trading, LLC | 37,310 | New | 0.02% | $0 M | Nov 4, 2026 |
Mutual funds holding Cabaletta Bio, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc. | 7.87 M | $24 M | 4.7% | 0.23% | +36% | Jun 30, 2026 |
| 🇺🇸 PGIM Jennison Health Sciences FundPGIM INVESTMENTS LLC | 4.96 M | $19 M | 3.0% | 1.4% | +41% | May 29, 2026 |
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 5.26 M | $16 M | 3.1% | 0.15% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 5.22 M | $16 M | 3.1% | <0.01% | +84% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 2.93 M | $9 M | 1.8% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 PGIM Jennison Small Company FundPrudential Jennison Small Co Fund, Inc. | 2.70 M | $8 M | 1.6% | 0.24% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.88 M | $6 M | 1.1% | <0.01% | +71% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 1.80 M | $6 M | 1.1% | 0.05% | +195% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Stock Fund, Inc.T. Rowe Price Associates, Inc. | 1.39 M | $4 M | 0.83% | 0.05% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc. | 1.37 M | $4 M | 0.82% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.23 M | $3 M | 0.74% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 1.01 M | $3 M | 0.60% | 0.03% | +59% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 662,486 | $3 M | 0.40% | <0.01% | +8.2% | May 31, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 876,846 | $2 M | 0.52% | 0.20% | new | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Institutional Small-Cap Stock FundT. Rowe Price Associates, Inc. | 746,576 | $2 M | 0.45% | 0.05% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 523,569 | $2 M | 0.31% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 486,921 | $2 M | 0.29% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Value PortfolioMason Street Advisors, LLC | 485,013 | $2 M | 0.29% | 0.23% | +52% | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 496,689 | $1 M | 0.30% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 448,514 | $1 M | 0.27% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 373,752 | $1 M | 0.22% | 0.08% | +60% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 279,599 | $1 M | 0.17% | <0.01% | +61% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 334,526 | $1 M | 0.20% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 224,492 | $1 M | 0.13% | <0.01% | +62% | May 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 303,059 | $1 M | 0.18% | 0.08% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 301,437 | $1 M | 0.18% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 274,359 | $1 M | 0.16% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 PGIM Jennison Blend FundPGIM INVESTMENTS LLC | 192,216 | $1 M | 0.11% | 0.06% | new | May 29, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 210,446 | $1 M | 0.13% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 202,673 | $1 M | 0.12% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 178,606 | $0 M | 0.11% | 0.10% | new | Jul 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 172,727 | $0 M | 0.10% | 0.02% | −7.4% | Jul 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 149,656 | $0 M | 0.09% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 122,955 | $0 M | 0.07% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 122,675 | $0 M | 0.07% | 0.26% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 110,667 | $0 M | 0.07% | 0.05% | +149% | Jun 30, 2026 |
| 🇺🇸 Small Company Value TrustJohn Hancock Variable Trust Advisers LLC | 108,215 | $0 M | 0.06% | 0.22% | +54% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P. | 115,487 | $0 M | 0.07% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 113,690 | $0 M | 0.07% | <0.01% | +125% | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 82,200 | $0 M | 0.05% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 67,179 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 93,819 | $0 M | 0.06% | <0.01% | +89% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 77,990 | $0 M | 0.05% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 76,892 | $0 M | 0.05% | <0.01% | +49% | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 80,701 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P. | 66,996 | $0 M | 0.04% | 0.06% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 57,487 | $0 M | 0.03% | <0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Spectrum Moderate Growth Allocation FundT. Rowe Price Associates, Inc. | 47,082 | $0 M | 0.03% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 55,350 | $0 M | 0.03% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 53,371 | $0 M | 0.03% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 60,355 | $0 M | 0.04% | <0.01% | +80% | Jul 31, 2026 |
| 🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS | 51,836 | $0 M | 0.03% | 0.07% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 48,754 | $0 M | 0.03% | 0.07% | new | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 46,561 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 53,547 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 44,710 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 44,710 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 44,137 | $0 M | 0.03% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC | 42,068 | $0 M | 0.03% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 38,100 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 37,844 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 37,200 | $0 M | 0.02% | 0.05% | +1606% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 32,378 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 AST PGIM Aggressive Multi-Asset PortfolioAST Investment Services, Inc. | 30,758 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 30,249 | $0 M | 0.02% | <0.01% | +99% | Jun 30, 2026 |
| 🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC | 26,242 | $0 M | 0.02% | 0.05% | +2383% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 25,212 | $0 M | 0.02% | 0.04% | +54% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 25,098 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 23,375 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 25,464 | $0 M | 0.02% | 0.02% | +75% | Jul 31, 2026 |
| 🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC | 21,833 | $0 M | 0.01% | 0.05% | new | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 17,404 | $0 M | 0.01% | <0.01% | −78% | May 31, 2026 |
| 🇺🇸 T. Rowe Price Spectrum Moderate Allocation FundT. Rowe Price Associates, Inc. | 17,019 | $0 M | 0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 22,315 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 18,071 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 17,651 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 19,980 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 17,171 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 17,765 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 15,250 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 14,700 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 16,490 | $0 M | <0.01% | <0.01% | +71% | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 13,592 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Spectrum Conservative Allocation FundT. Rowe Price Associates, Inc. | 11,160 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 15,719 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust | 9,741 | $0 M | <0.01% | 0.03% | no change | May 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 13,183 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 10,217 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 9,002 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 8,841 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 9,987 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 8,572 | $0 M | <0.01% | <0.01% | −7.9% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 8,596 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 8,511 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 7,785 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC | 6,148 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 5,179 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 5,084 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 4,836 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 5,304 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Cabaletta Bio, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | David J. ChangChief Medical Officer | Buy | +8,800 | $2.260 | $20 K | 8,800 | Form 4 |
| filed | Catherine BollardDirector | Buy | +4,405 | $2.270 | $10 K | 5,405 | Form 4 |
| filed | Michael GerardGeneral Counsel | Buy | +6,600 | $2.270 | $15 K | 6,600 | Form 4 |
| filed | Shawn TomaselloDirector | Buyindirect | +22,725 | $2.210 | $50 K | 22,725 | Form 4 |
| filed | Mark SimonDirector | Buy | +11,061 | $2.280 | $25 K | 147,205 | Form 4 |
| filed | Steven NichtbergerPresident & CEO, Director | Buy | +45,000 | $2.240 | $101 K | 1.03 M | Form 4 |
| filed | Steve GavelChief Commercial Officer | Buy | +22,170 | $2.270 | $50 K | 22,170 | Form 4 |
| filed | Gwendolyn BinderPresident, Science & Tech. | Buy | +11,312 | $2.190 | $25 K | 31,312 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Cabaletta Bio, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-1.49 reverse split
Trading halts
- 2024-11-29 14:38 UTC, code LUDP, resumed 14:43 UTC
Fails to deliver
- : 35,869 shares at $1.59
- : 100 shares at $1.52
- : 1 shares at $1.41
- : 3,695 shares at $1.97
- : 809 shares at $2.02
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Cabaletta Bio, Inc. scorecard#
Passes 1 of the 12 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.1×Price to book 3.1× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-38.6%Free cash flow is -38.6% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.10 vs -2.34Diluted EPS -2.10 in fiscal 2025 against -2.34 the year before (report's currency).
- ✗Net income higher than five years earlier-$168 M-$168 M in fiscal 2025 against -$33 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$168 MNet income -$168 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-127.0%-127.0% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.8×Current ratio 2.77 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-86.1×Operating income -86.1 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Cabaletta Bio, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Research and development | 143+46.8%— | 97+75.4%— | 55+41.0%— | 39+20.9%— | 32+52.0%— | 21+83.2%— | 12+161%— | 4.5—— | |
| General and administrative | 30+5.8%— | 28+45.2%— | 19+29.6%— | 15+7.4%— | 14+10.9%— | 12+77.7%— | 7.0+306%— | 1.7—— | |
| Operating expenses | 172+37.6%— | 125+67.6%— | 75+37.9%— | 54+16.9%— | 46+36.9%— | 34+81.1%— | 19+202%— | 6.2—— | |
| Operating income | −172—— | −125—— | −75—— | −54—— | −46—— | −34—— | −19—— | −6.2—— | |
| Interest and finance income | 6.0−39.8%— | 10+43.5%— | 7.0+500%— | 1.2+4750%— | 0.0−95.1%— | 0.5−71.6%— | 1.7+640%— | 0.2—— | |
| Interest expense and finance costs | 2.0+168%— | 0.7—— | 0—— | — | — | — | — | — | |
| Income tax | 0—— | 0—— | — | — | — | — | — | — | |
| Net income including minority interests | −168—— | −116—— | −68—— | −53—— | −46—— | −33—— | −17—— | −12—— | |
| Net income attributable to shareholders | −168—— | −116—— | −68—— | −53—— | −46—— | −33—— | −17—— | −12—— | |
| Earnings per share, basic | -2.10—— | -2.34—— | -1.65—— | -1.81—— | -1.80—— | -1.44—— | -4.07—— | -6.87—— | |
| Earnings per share, diluted | -2.10—— | -2.34—— | -1.65—— | -1.81—— | -1.80—— | -1.44—— | -4.07—— | -6.87—— | |
| Shares, weighted average (basic) | — | — | 1.2−80.3%— | 5.9—— | — | — | — | — | |
| Dividends per share | — | — | — | — | — | — | 0.00—— | — | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 83−49.4%50.3% | 164−15.2%88.6% | 193+137%76.2% | 82−33.2%69.8% | 122+20.5%96.7% | 101−25.5%88.4% | 136+313%96.3% | 33—96.6% | |
| Short-term investments | 51—30.7% | 0−100%0.0% | 48+92.5%18.9% | 25—21.3% | 0−100%0.0% | 7.2—6.3% | — | — | |
| Other current assets | 5.3+94.3%3.2% | 2.7−16.3%1.5% | 3.2+41.7%1.3% | 2.3−1.4%2.0% | 2.3−52.4%1.8% | 4.9+12.1%4.2% | 4.3+345%3.1% | 1.0—2.9% | |
| Current assets | 139−16.7%84.1% | 167−31.8%90.1% | 244+125%96.4% | 109−12.6%93.0% | 125+9.7%98.6% | 114−19.2%99.0% | 141+313%99.4% | 34—99.5% | |
| Property, plant and equipment | 1.9−29.9%1.2% | 2.7+7.9%1.5% | 2.5−1.4%1.0% | 2.6+79.3%2.2% | 1.4+61.6%1.1% | 0.9+9.2%0.8% | 0.8—0.6% | — | |
| Right-of-use (leased) assets | 3.4−45.7%2.1% | 6.3+28.6%3.4% | 4.9−1.6%1.9% | 5.0—4.3% | 0—0.0% | — | — | — | |
| Total assets | 165−10.8%100% | 185−27.0%100% | 254+117%100% | 117−7.4%100% | 126+10.1%100% | 115−18.9%100% | 141+314%100% | 34—100% | |
| Accounts payable | 6.6+34.8%4.0% | 4.9+8.3%2.7% | 4.5+84.6%1.8% | 2.5+5.6%2.1% | 2.3+87.7%1.8% | 1.2+35.1%1.1% | 0.9+52.6%0.7% | 0.6—1.8% | |
| Current liabilities | 50+85.2%30.4% | 27+69.4%14.6% | 16+68.6%6.3% | 9.5+13.2%8.1% | 8.4+61.8%6.6% | 5.2+64.6%4.5% | 3.1+234%2.2% | 0.9—2.8% | |
| Lease liabilities (non-current) | 0−100%0.0% | 2.4+63.5%1.3% | 1.5−50.7%0.6% | 3.0—2.5% | 0—0.0% | — | — | — | |
| Total liabilities | 53+62.1%32.1% | 33+87.4%17.7% | 17+40.2%6.9% | 12+48.5%10.6% | 8.4—6.6% | — | — | — | |
| Retained earnings | −517—−313% | −349—−189% | −233—−92.0% | −166—−142% | −113—−89.1% | −66—−57.8% | −33—−23.3% | −12—−36.4% | |
| Shareholders' equity | 112−26.4%67.9% | 152−35.5%82.3% | 236+126%93.1% | 105−11.4%89.4% | 118+7.7%93.4% | 110−20.8%95.5% | 138—97.8% | −11—−31.3% | |
| Total liabilities and equity | 165−10.8%100% | 185−27.0%100% | 254+117%100% | 117−7.4%100% | 126+10.1%100% | 115−18.9%100% | 141+314%100% | 34—100% | |
| Shares outstanding | 100+98.0%— | 51+6.1%— | 48+62.4%— | 29+1.8%— | 29+20.2%— | 24+0.1%— | 24+525%— | 3.8—— | |
| Cash-flow statement | |||||||||
| Share-based compensation | 21+7.6%— | 19+71.6%— | 11+64.5%— | 6.9+18.8%— | 5.8+32.3%— | 4.4+90.8%— | 2.3+280%— | 0.6—— | |
| Cash from operating activities | −131—— | −88—— | −54—— | −46—— | −34—— | −27—— | −16—— | −4.7—— | |
| Capital expenditure | −1.2—— | −2.2—— | −0.7—— | −2.5—— | −1.2—— | −0.6—— | −0.7—— | — | |
| Cash from investing activities | −50−206%— | 47—— | −22—— | −27−554%— | 6.0—— | −8.0—— | −0.7—— | — | |
| Shares issued | 94—— | 0r11−100%— | 185+464%— | 33−31.9%— | 48—— | −0.2−100%— | 71—— | — | |
| Cash from financing activities | 100+759%— | 12−93.8%— | 188+469%— | 33−32.6%— | 49—— | −0.0−100%— | 120+218%— | 38—— | |
| Exchange-rate effect on cash | 0.0—— | −0.0—— | 0—— | — | — | — | — | — | |
| Change in cash | −81—— | −29−126%— | 112—— | — | — | — | — | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 165+25.1%— | 47+18.4%— | 44+18.0%— | 37+28.7%— | 36*+41.8%— | 40+51.5%— | 38+60.7%— | 29+32.2%— | 26*+46.7%— | 26—— | 23—— | 22—— | 17*—— | |
| General and administrative | 29−9.2%— | 7.6+11.8%— | 7.6−8.2%— | 6.9−14.5%— | 6.4*−22.2%— | 6.8+0.1%— | 8.3+20.7%— | 8.1+33.6%— | 8.3*+43.8%— | 6.8—— | 6.9—— | 6.1—— | 5.7*—— | |
| Operating expenses | 194+18.5%— | 55+17.4%— | 52+13.3%— | 44+19.3%— | 43*+26.1%— | 47+41.0%— | 46+51.6%— | 37+32.5%— | 34*+46.0%— | 33—— | 30—— | 28—— | 23*—— | |
| Operating income | −194—— | −55—— | −52—— | −44—— | −43*—— | −47—— | −46—— | −37—— | −34*—— | −33—— | −30—— | −28—— | −23*—— | |
| Interest and finance income | 6.2−7.5%— | 2.1+18.6%— | 1.6+13.8%— | 1.1−27.6%— | 1.3*−31.9%— | 1.8−25.2%— | 1.4−47.3%— | 1.5−50.2%— | 1.9*−13.8%— | 2.4—— | 2.7—— | 3.0—— | 2.3*—— | |
| Interest expense and finance costs | 2.2+1.0%— | 0.5−12.5%— | 0.5−9.5%— | 0.6+116%— | 0.6*−25.8%— | 0.6—— | 0.6—— | 0.3—— | 0.7*—— | 0—— | 0—— | 0—— | — | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | — | |
| Net income including minority interests | −190—— | −53*—— | −51*—— | −44—— | −42*—— | −45*—— | −45*—— | −36—— | −33*—— | −31*—— | −28*—— | −25—— | −21*—— | |
| Net income attributable to shareholders | −190—— | −53—— | −51—— | −44—— | −42*—— | −45—— | −45—— | −36—— | −33*—— | −31—— | −28—— | −25—— | −21*—— | |
| Earnings per share, basic | — | -0.28—— | -0.34—— | -0.39—— | — | -0.44—— | -0.73—— | -0.71—— | — | -0.62—— | -0.56—— | -0.51—— | — | |
| Earnings per share, diluted | — | -0.28—— | -0.34—— | -0.39—— | — | -0.44—— | -0.73—— | -0.71—— | — | -0.62—— | -0.56—— | -0.51—— | — | |
| Shares, weighted average (basic) | 187+82.7%— | 187+82.7%— | 151+144%— | 112+121%— | — | 102—— | 62—— | 51+4244%— | — | — | — | 1.2—— | — | |
| Shares, weighted average (diluted) | 187+82.7%— | 187+82.7%— | 151+144%— | 112+121%— | — | 102—— | 62—— | 51—— | — | — | — | — | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 299—89.0% | 299+397%89.0% | 225+54.6%87.7% | 117−11.5%78.7% | 83−49.4%50.3% | 60−64.7%31.7% | 146−18.5%64.9% | 132−24.8%79.8% | 164−15.2%88.6% | 171—83.5% | 179—82.2% | 175—72.9% | 193—76.2% | |
| Short-term investments | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0—0.0% | 51—30.7% | 100+704%52.6% | 49+99.4%21.9% | — | 0−100%0.0% | 12—6.1% | 25—11.3% | 49—20.2% | 48—18.9% | |
| Other current assets | 10—3.1% | 10+126%3.1% | 5.9+59.2%2.3% | 5.7+105%3.8% | 5.3+94.3%3.2% | 4.6+85.0%2.4% | 3.7+22.9%1.7% | 2.8−23.9%1.7% | 2.7−16.3%1.5% | 2.5—1.2% | 3.0—1.4% | 3.6—1.5% | 3.2—1.3% | |
| Current assets | 310—92.1% | 310+88.3%92.1% | 231+16.4%90.0% | 122−9.1%82.6% | 139−16.7%84.1% | 165−11.3%86.7% | 198−3.8%88.4% | 135−40.8%81.5% | 167−31.8%90.1% | 186—90.8% | 206—94.9% | 227—94.6% | 244—96.4% | |
| Property, plant and equipment | 1.0—0.3% | 1.0−51.1%0.3% | 1.5−37.7%0.6% | 1.6−39.9%1.1% | 1.9−29.9%1.2% | 2.1−26.7%1.1% | 2.4−20.2%1.1% | 2.6−9.6%1.6% | 2.7+7.9%1.5% | 2.8—1.4% | 3.0—1.4% | 2.9—1.2% | 2.5—1.0% | |
| Right-of-use (leased) assets | 4.7—1.4% | 4.7+30.8%1.4% | 5.7+25.5%2.2% | 2.5−54.9%1.7% | 3.4−45.7%2.1% | 3.6−73.6%1.9% | 4.5−23.7%2.0% | 5.4−29.3%3.3% | 6.3+28.6%3.4% | 14—6.7% | 5.9—2.7% | 7.7—3.2% | 4.9—1.9% | |
| Total assets | 336—100% | 336+77.3%100% | 257+14.4%100% | 148−10.3%100% | 165−10.8%100% | 190−7.2%100% | 225+3.3%100% | 165−31.3%100% | 185−27.0%100% | 204—100% | 217—100% | 240—100% | 254—100% | |
| Accounts payable | 9.0—2.7% | 9.0+9.4%2.7% | 5.8−19.2%2.3% | 6.4−1.7%4.3% | 6.6+34.8%4.0% | 8.3+279%4.4% | 7.2+70.5%3.2% | 6.5+11.1%3.9% | 4.9+8.3%2.7% | 2.2—1.1% | 4.2—1.9% | 5.8—2.4% | 4.5—1.8% | |
| Current liabilities | 47—14.1% | 47+3.5%14.1% | 40−3.9%15.5% | 42+22.1%28.0% | 50+85.2%30.4% | 46+99.9%24.1% | 42+132%18.5% | 34+89.1%20.6% | 27+69.4%14.6% | 23—11.2% | 18—8.2% | 18—7.5% | 16—6.3% | |
| Lease liabilities (non-current) | 0.5—0.1% | 0.5—0.1% | 1.5+156%0.6% | — | 0−100%0.0% | 0−100%0.0% | 0.6—0.3% | 1.5+95.3%0.9% | 2.4+63.5%1.3% | 7.3—3.6% | 0—0.0% | 0.8—0.3% | 1.5—0.6% | |
| Total liabilities | 53—15.6% | 53+4.5%15.6% | 46+0.3%18.0% | 45+2.9%30.3% | 53+62.1%32.1% | 50+66.7%26.5% | 46+157%20.5% | 44+133%26.4% | 33+87.4%17.7% | 30—14.8% | 18—8.2% | 19—7.8% | 17—6.9% | |
| Retained earnings | −665—−197% | −665—−197% | −611—−238% | −560—−378% | −517—−313% | −475—−250% | −430—−192% | −385—−233% | −349—−189% | −317—−155% | −286—−131% | −258—−107% | −233—−92.0% | |
| Shareholders' equity | 284—84.4% | 284+104%84.4% | 211+18.0%82.0% | 103−15.0%69.7% | 112−26.4%67.9% | 139−20.0%73.5% | 178−10.5%79.5% | 122−45.2%73.6% | 152−35.5%82.3% | 174—85.2% | 200—91.8% | 222—92.2% | 236—93.1% | |
| Total liabilities and equity | 336—100% | 336+77.3%100% | 257+14.4%100% | 148−10.3%100% | 165−10.8%100% | 190−7.2%100% | 225+3.3%100% | 165−31.3%100% | 185−27.0%100% | 204—100% | 217—100% | 240—100% | 254—100% | |
| Shares outstanding | — | — | — | — | 100+98.0%— | 96+97.1%— | 91+89.4%— | — | 51+6.1%— | 49—— | 48—— | 48—— | 48—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 20−8.2%— | 5.3*−9.5%— | 5.5*−3.6%— | 5.3+1.8%— | 4.3*−21.3%— | 5.8*+10.8%— | 5.7*+13.8%— | 5.2+36.1%— | 5.4*+77.4%— | 5.3*—— | 5.0*—— | 3.8—— | 3.1*—— | |
| Cash from operating activities | −162—— | −43*—— | −42*—— | −43—— | −35*—— | −35*—— | −30*—— | −31—— | −23*—— | −20*—— | −21*—— | −24—— | −16*—— | |
| Capital expenditure | −0.3—— | −0.1*—— | 0*—— | 0—— | −0.2*—— | −0.1*—— | −0.2*—— | −0.8—— | −0.4*—— | −0.3*—— | −0.8*—— | −0.8—— | −0.2*—— | |
| Cash from investing activities | 101—— | −0.1*—— | 0*—— | 51—— | 50*+311%— | −50*−509%— | −49*−307%— | −0.8—— | 12*+967%— | 12*—— | 24*—— | −0.8—— | 1.1*—— | |
| Shares issued | 222—— | 115*—— | 6.3*—— | 6.9—— | 94r0*—— | 0r−0.0*—— | 0r94*—— | 0−100%— | 0r5.1*−100%— | 0r0*—— | −5.7r0*—— | 5.7—— | 92*—— | |
| Cash from financing activities | 301+212%— | 117*—— | 150*+60.6%— | 25—— | 8.3*+90.6%— | −0.8*−1235%— | 93*+24537%— | −0.6−108%— | 4.4*−95.3%— | 0.1*—— | 0.4*—— | 6.9—— | 93*—— | |
| Exchange-rate effect on cash | −0.0−757%— | −0.0*—— | −0.0*−123%— | −0.0−286%— | −0.0*—— | −0.0*—— | 0.0*—— | 0.0—— | −0.0*—— | 0*—— | 0*—— | 0—— | — | |
| Change in cash | 239—— | 74*—— | 108*+687%— | 34—— | 23*—— | −85*—— | 14*+315%— | −32—— | −6.6*—— | −8.0*—— | 3.3*—— | −18—— | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Cabaletta Bio, Inc. operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office1 subsidiary | — |
| 🇩🇪 Germany | 1 subsidiary | — |
| 🇨🇭 Switzerland | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Cabaletta Bio, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Steven Nichtberger | $1.9 M | $1.7 M | $973 K | $24 |
| 2024Steven Nichtberger | $8.1 M | −$8.6 M | $3.4 M | $25 |
| 2023Steven Nichtberger | $4.8 M | $14.5 M | $2.2 M | $245 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Cabaletta Bio, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 1 · Material agreement 2 · Agreement ended 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementResults announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Agreement ended | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Cabaletta Bio, Inc.#
$50 K spent on lobbying the US Congress and federal agencies in 2025, most often on medicare/medicaid.
- Medicare/Medicaid2 reports
Lobbying firms hired in 2025
Hogan Lovells US LLP $50 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2025 | $50 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Cabaletta Bio”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How Cabaletta Bio, Inc. compares in Biotechnology
- Market cap$343 M · higher than 53% of 726
- Price / book3.1× · lower than 48% of 534
- FCF yield-38.6% · higher than 29% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Cabaletta Bio, Inc.🇺🇸 | $343 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Cabaletta Bio, Inc.? Verify and update this profile — free
Show Cabaletta Bio, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.